Shots:
- Insilico Medicine & Hygtia Therapeutics have entered into a co-development global collaboration agreement for Insilico’s ISM8969 program for CNS disorders
- As per the deal, Hygtia will receive 50% worldwide rights to research, develop, register, manufacture, & commercialize ISM8969 in exchange for ~$66M, incl. milestone payments & $10M initial upfront payment
- Under the agreement, Insilico will advance early development for Parkinson’s disease, incl. IND filing & P-I execution, while Hygtia will lead global late-stage trials, regulatory filings, & commercialization
Ref: PRnewswire | Image: Insilico Medicine & Hygtia|Press Release
Related News: Insilico Medicine and TaiGen Biotechnology Partner for ISM4808 to Treat Anemia of Chronic Kidney Disease (CKD)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
